United Therapeutics Corporation (UTHR)
-NasdaqGS 69.17 
0.69(1.01%) May 17, 4:00PM EDT|After Hours
:
68.72 0.45 (0.65%) May 17, 4:15PM EDT
| Prev Close: | 68.48 |
|---|
| Open: | 68.61 |
|---|
| Bid: | 65.50 x 100 |
|---|
| Ask: | 76.69 x 100 |
|---|
| 1y Target Est: | 55.17 |
|---|
| Beta: | 1.41 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 67.71 - 69.21 |
|---|
| 52wk Range: | 41.75 - 69.21 |
|---|
| Volume: | 515,066 |
|---|
| Avg Vol (3m): | 836,700 |
|---|
| Market Cap: | 3.44B |
|---|
| P/E (ttm): | 12.31 |
|---|
| EPS (ttm): | 5.62 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Innovative Therapeutic Development for Duchenne Muscular Dystrophy Moves Niche Stocks Up 300% to 400%: An Expert Portfolio Manager Discusses Investing in Health CareWall Street Transcript(Thu, May 16)
- Organovo: Get Rich Or Die Tryin'at Seeking Alpha(Wed, May 15)
- United Therapeutics downgraded by Standpoint ResearchBriefing.com(Wed, May 15)
- United Stock Hits New 52-Week High (UTHR)at TheStreet(Tue, May 14)
- Gilead Shows Some Heartat Motley Fool(Wed, May 8)
- Industry Ranks May 2013at Seeking Alpha(Mon, May 6)
- Three Mid-Cap Stocks To Keep An Eye Onat Motley Fool(Thu, May 2)
- Alternative Generic Drug Products to Sustain Decent Margins and Cash Flow Generation Over the Long Term: Expert Analyst David Amsellem Discusses the Generic Drug Space with The Wall Street TranscriptWall Street Transcript(Thu, May 2)
- United Rises On Unusually High Volume (UTHR)at TheStreet(Tue, Apr 30)
- Indexes Recover Early Losses As Turnover Picks Upat Investor's Business Daily(Tue, Apr 30)
- UNITED THERAPEUTICS CORP FinancialsEDGAR Online Financials(Tue, Apr 30)
- United Therapeutics' Second PAH Stumble Emphasizes The Need For Pluristem's Therapyat Seeking Alpha(Tue, Apr 30)
- Investors Ride 5 Healthcare Earnings Rollercoaster Ridesat Wall St. Cheat Sheet(Sun, Apr 28)
- Biogen Earnings Strong, But Celgene Just So-SoInvestor's Business Daily(Thu, Apr 25)
- United Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, Apr 25)
Key Statistics
| Forward P/E (1 yr): | 9.71 |
|---|
| P/S (ttm): | 3.56 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 6.22 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.47 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | 0.28 |
|---|
Business Summary
United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide.
View More